Perrigo Company plc (PRGO) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Hello, and welcome, everyone, whether you're joining us this morning or this afternoon. This is Perrigo's conference call covering our earnings for the second quarter of 2026. You can find a copy of the release we put out today, along with the presentation that goes with it, in the Investors section on perrigo.com. On the call with us today are Albert Manzone, who is serving as Perrigo's Interim President and CEO, and our CFO, Eduardo Bezerra. Some of what participants say during this presentation will consist of forward-looking statements. For details about those statements, which carry significant risks and uncertainties, please look at the slides; we'll also be citing adjusted financial measures, which are non-GAAP in nature. Additional information, including reconciliations of every non-GAAP measure presented to the corresponding GAAP measure, appears in the appendix to the earnings presentation. Now let's go to the agenda. Albert will begin by talking about the leadership transition and what his priorities are. After that, he'll go over how we're doing against the Three-S plan, give an overview of the market, and walk through how we performed in the second quarter. To wrap up his remarks, Albert will give an update on the key priorities that we expect will help drive better execution and create long-term value. Eduardo will follow with a financial review and cover our outlook for 2026; with that, I'll hand things over to Albert.
Appreciate that, Eric. Greetings, everyone, whether it's morning or afternoon where you are, and thanks for being on the call today. To begin, I want to say that taking on the role of Perrigo's Interim President and CEO is both an honor and a tremendous responsibility. To our customers, our investors and my Perrigo colleagues, let me give you this assurance: my commitment to our mission — being a world leader in affordable consumer self-care — is total, at 100%. There is significant work in front of us, and I am acting swiftly to move our key priorities forward. I've been a member of Perrigo's Board since 2022, and over a career spanning more than 30 years, I've led and transformed consumer businesses at pivotal inflection points, OTC Healthcare among them. This company is familiar to me, and I see clearly what is required to generate value here. My first month was spent on the road, listening. Three things stand out. First, our customers. What Perrigo delivers to the market matters to them, and they're eager to expand their business with us; there's a great deal we can offer and a clear right to win. Second, our investors. I've heard from them directly. Trust from the investment community has to be won back, and I take that personally. Third, let's talk about our people. This group brings a wealth of experience and possesses everything needed to achieve the objectives we've set. We also welcomed two highly capable new Board members this quarter, Salman Amin and Omer Gajial, and their backgrounds in consumer, operations and strategy will be valuable in guiding our value creation efforts. What I want to convey today is straightforward: the Board, the management team and I all have strong confidence in what lies ahead for Perrigo. First, let me explain who we are. When it comes to store brand OTC in the U.S., we are the leader, and in Europe, several products within our OTC brands portfolio are category leaders in their own right. Store brand and branded account for about half of sales each, though that balance is not evenly distributed across geographies. Almost all of that comes from store brand in the U.S., while in Europe it's nearly all branded. No other company in our industry has that kind of mix. Our category-led operating model and One Perrigo approach let us reach shoppers through brands, store brands, categories and price points — something that matters more and more as people pay closer attention to value. During Q2, those strengths helped us pick up market share throughout our portfolio, despite ongoing difficulties in the categories where we compete. The U.S. stood out in particular, with gains in dollar, unit and volume consumption. As the quarter went on, things got better in our categories, and that positive trend is continuing into Q3. We're also restating our outlook for the whole of 2026, with more weight on the back half and backed by specific, concrete drivers. We're staying aware that consumers and the economy remain unpredictable, but our focus is on the areas we can control: picking up share, simplifying what we offer, and paying down debt. Everything we're doing fits within the Three-S plan — Stabilize, streamline and strengthen. When it comes to Stabilize, we've made our operations more consistent, improved service levels, and sharpened how we execute in important categories. U.S. service levels are up 1,600 basis points since 2023, now at 91%, and internationally they've increased 1,000 basis points to 95%. Stronger service has deepened our customer relationships and directly fueled our share gains; with Streamline, we've simplified the portfolio, reinforced the balance sheet, and removed costs. Since 2024, divestitures have brought in roughly $600 million of upfront proceeds, mostly directed toward paying down debt, including this quarter's $359 million sale of Dermacosmetics. Our operational enhancement program remains on track to generate $80 million to $100 million in savings by 2027; we're also moving forward with strategic reviews of Infant Formula and Oral Care, evaluating whether to optimize, partner, or divest each one. Our approach is disciplined. No matter how those reviews turn out, the result has to increase shareholder value and make the portfolio more sharply focused. At the same time, we have improved the Infant Formula business by rationalizing capacity, boosting efficiency, and pursuing innovation. Those actions have brought about more stability, clearer visibility, and a sturdier business regardless of what the reviews ultimately decide. When it comes to Strengthen, we have built up the capabilities that will drive growth going forward: a new operating model led by category, a substantially larger innovation pipeline, closer collaboration with retailers, and more effective demand generation. Since 2024, the worth of our innovation pipeline has grown to more than three times its previous level, and shared platforms are now used by over 55% of projects. As a result, our investment is both more efficient and more scalable, which is fueling share gains in U.S. store brand OTC and in key European brands. Taken as a whole, our Three-S plan has given us a leaner organization and something to build on. There's still plenty left to do, yet the business has encouraging momentum and the direction forward is obvious. Briefly, on the market: consumption is still under long-term norms, even as it gets better. Through the quarter, U.S. value and volume patterns showed sequential gains, and Europe also moved higher. Those gains have continued into the third quarter. In the 4 weeks ended July 19, U.S. OTC volumes across the categories we play in went positive. Weakness has been centered on seasonal categories in the self-care segment, such as cough, cold, pain and allergy, which mirrors reduced seasonal incidence and difficult year-over-year comparisons. We're treating this dip as short-lived, and it hasn't shifted how we think about demand over the long haul. As the year goes on and year-over-year comparisons get easier, we anticipate category trends will continue getting better. Our mission is broadening access to high-quality, reasonably priced self-care, and with shoppers so focused on value right now, that mission matters more than ever. That fit, combined with stronger execution and a model that stands apart, is driving share gains we can actually measure. On the U.S. side, the segments where we play saw a 1.1% drop in volume. Even so, our store brand OTC volumes rose 1.5% when you combine health care and Specialty Care, which lifted our market share by 50 basis points. Over in Europe, category value fell 0.6%, but our key brands were up 3.3%, and that also delivered a 50 basis point share gain. Those improvements in share come from our growth building blocks, and a handful of examples illustrate how the model works. Opill continues to build momentum in its second year, with velocities rising at key retailers, strong repeat purchase behavior, and shoppers trading up to larger pack sizes. That shows how targeted demand generation paired with focused innovation can grow a category. During the quarter, Compeed gained momentum, driven by an earlier start to seasonal activation and better in-store execution across Europe. That led to share gains and record retail sales. It shows how brand investment, combined with commercial execution, can deliver results. In the meantime, our store brand allergy business kept gaining share, helped by innovation, distribution wins, and demand generation that is lifting household penetration. What brings all of this together is a more integrated, more scalable engine — a single category-led model, a single innovation pipeline used across categories, markets, and price points. Before Eduardo takes you through the details, let me briefly cover the numbers. When you look at core net sales, they were down 3.1% from a year ago, while total net sales declined 3.2%. The pressure came from a few places: the category has stayed soft relative to a tough comparison last year, summer categories got off to a slow start, and retailers pulled back on inventory. Within the total figure, Infant Formula grew 23%, but that gain was more than wiped out by the Dermacosmetics divestiture. On the bottom line, core adjusted EPS was $0.46, and adjusted EPS on an all-in basis was $0.50. We came in ahead of our expectations, largely thanks to some onetime cost benefits, which is why we're holding our outlook steady instead of raising it.
The things we care about most — share of the market, how well we execute, savings on costs, bringing down debt and actions on our portfolio — are all moving in the right direction. We called 2026 a year of transition, where weaker reported numbers in the first half would mask real progress operationally, and that is precisely what happened; our share keeps climbing, a clear sign the strategy is working and that we'll gain once demand returns to normal. Meanwhile, the building blocks of our growth — innovation, generating demand and distribution — are setting us up for a stronger second half in sequential terms. Let me end by talking about where we're headed, since that's what will shape what Perrigo becomes. To start, we'll keep growing our market share by widening access to quality self-care products that people can afford. Within America, we're aiming not just to capture a bigger slice of the store brand OTC market but to make that whole market bigger. There's a lot of untapped potential with store brands, and our partnerships with retail customers put us in a special spot to bring additional shoppers quality self-care at a stronger value, which grows the category. Over in Europe, brands such as Compeed and Jungle Formula are category leaders for us. We're putting money behind those winners and directing our resources toward the places where we have the best shot at winning. That lets us stay agile and competitive in whatever areas we decide to compete in. Next, we'll keep making our portfolio simpler and stronger so we can sharpen focus, discipline and consistency. The steps we've implemented in recent years—such as reshaping our portfolio and conducting continuous strategic assessments—are assisting us in building a consumer health-care business that is more concentrated and reliable. Next, we intend to reinforce the balance sheet and keep reducing our debt, which affords us room to put money to work and generate value. Our blueprint is designed to produce gains on important measures, among them improved revenue expansion, healthier profit margins, and diminished borrowing. So that our approach to deploying capital stays consistent with both our strategy and the opportunities the market presents, we routinely examine where capital can be used most effectively—whether for growth-oriented investments, paying down debt, or returning money to shareholders—and that includes evaluating the dividend every quarter; yet I want to state this plainly. We need to meet what we've promised for 2026, and at the same time make sure Perrigo is set up for growth that lasts over the long haul. Two areas will get my attention above all else: our strategy and how well we execute. Perrigo is turning into a consumer self-care business with a sharper focus, and I have strong confidence that we're creating genuine, lasting value for shareholders. With that, I'll hand things to Eduardo so he can take you through the financials in greater depth.
Thanks, Albert, and good morning, everyone. Before I get going, I should point out that unless I'm talking about net sales, all of my comments will be on an adjusted, non-GAAP basis. Let me start at the top line. Core net sales declined 3.1% from a year earlier, while Core organic net sales dropped 3.5%. Two things dragged on these numbers: about 1.2% stemmed from lingering softness in category consumption set against a tough comparison from the prior year, particularly in cough, cold and certain summer seasonal categories; and roughly 1.8% came from retailers continuing to draw down inventory, with Europe hit hardest. Even though those pressures held back reported results, category trends improved as the quarter progressed, which strengthens our confidence in the underlying trajectory of the business. In Self-Care, results were shaped by sustained category softness and a summer season that started slowly. That softness was most pronounced in Europe, where allergy and sun seasons showed up late, pressuring demand across seasonal categories. Despite those headwinds, we continued gaining market share in key categories, supported by innovation and wider distribution, including a strong performance in our store brand allergy business on the back of distribution wins in the U.S. Specialty Care net sales dipped slightly. Strong growth in women's health reflected continued momentum for Opill and ellaOne, helped by solid consumer engagement, encouraging repeat purchase behavior, and ongoing outreach to health care professionals along with expanded distribution in Europe. Skin Health results were hurt by a slower start to key summer seasonal categories, lower sales of store brand Minoxidil, and a difficult comparison a year ago in Mederma related to the timing of inventory restocking. On a brighter note, trends improved as the quarter went on, with leading brands such as Compeed gaining speed as seasonal demand picked up in Europe. On an all-in basis, net sales declined 3.2%, reflecting the same category dynamics plus the effect of the Dermacosmetics divestiture. Partly offsetting that drop was strong performance in Infant Formula, which rose 23% year-over-year, driven by the timing of contract sales and growth in store brand formula. Currency translation provided a modest boost to both Core and all-in net sales in the quarter. Now let me move to adjusted operating income, which improved by roughly $16 million versus the prior year. Starting with Self-Care, all-in operating income declined $15 million, or 16.2%, largely due to lower net sales volumes, planned under-absorption stemming from lower prior year sales volumes in U.S. OTC, and unfavorable mix. We also felt pressure from continued retailer inventory reductions in Europe and a slow start to the summer season, which weighed on several higher-margin seasonal categories. Partially offsetting these headwinds were benefits from our operational enhancement program. Specialty Care operating income fell $18 million, or about 28%, primarily because of lower profitability in Skin Health, reflecting a slower start to key summer seasonal categories, retailer inventory reductions and lower contract manufacturing sales of store brand Minoxidil. Segment performance was likewise influenced by higher advertising and promotional outlays meant to support second-half growth initiatives, including a refreshed Opill marketing campaign, along with the impact of planned under-absorption stemming from reduced prior-year sales volumes. Turning to Infant Formula, operating income climbed about $60 million versus the prior year, as capacity rationalization, efficiency improvements, and business stabilization efforts continued to gain traction; additionally, the business benefited from lapping isolated production variability in the same period last year, which had elevated product scrap and hurt profitability. Operating income also improved by approximately $16 million year over year. Those factors more than offset planned under-absorption linked to lower sales volumes from the prior year. Within All Other, operating income was flat against the prior year, aided by net recognition of a recovered portion of tariffs paid earlier, as well as stronger profitability in Oral Care. Those items offset the impact of the Dermacosmetics divestiture. Corporate operating expenses declined versus a year ago, supported by savings from the operational enhancement program and a onetime benefit of $6 million related to the second quarter CEO transition. Moving now to margins. The drivers behind both Core and all-in margin changes aligned with the segment results just discussed. Core adjusted gross margin declined 250 basis points to 37%, primarily due to lower sales volumes, planned under-absorption tied to reduced prior-year sales volumes, and unfavorable mix. All-in adjusted gross margin declined 250 basis points to 35.6% from the same drivers affecting Core gross margin plus the impact of divestitures. Those drivers were partly offset by strong performance in the Infant Formula category. Core adjusted operating margin declined 160 basis points to 13%, reflecting gross margin flow-through, partly cushioned by gains from the operational enhancement program and the onetime benefit from the CEO transition. All-in adjusted operating margin declined 60 basis points to 12.2% from the same drivers as Core operating margin plus Infant Formula performance, which more than offset the impact of divestitures. Second quarter Core adjusted earnings per share came to $0.46, down $0.12 from the same period last year, yet ahead of what we expected, mainly because of lower operating expenses during the quarter, helped by faster implementation of our operational enhancement program plus a onetime benefit from the CEO transition. All-in adjusted diluted earnings per share dropped $0.07 to $0.50 because of the impact of lower sales volumes and the carryover effect of prior year manufacturing volumes, partly offset by the timing of Infant Formula contract business. Now on to cash flow. Second quarter 2026 cash from operating activities reached $83 million, matching what we expected. Capital expenditures came to $14 million, and we returned $40 million to shareholders via dividends. Now on to the balance sheet. Cash and cash equivalents stood at $400 million and total debt was $3.3 billion. In the quarter, the bulk of the $359 million in cash we received from selling Dermacosmetics went toward reducing our debt, which brought down by a substantial amount what was drawn on our revolving credit facility. Our approach to capital allocation remains disciplined — we aim to balance capex tied to growth, debt reduction on the balance sheet, and giving value back to shareholders. Looking ahead, first half earnings beat what we had expected, yet with the external environment changing and the timing of Infant Formula contract sales, we're taking a cautious approach in planning for the rest of the year. So our full year outlook for Core and all-in net sales, as well as margin and earnings per share metrics, stays where it was. The assumptions behind that outlook remain the same, among them continued momentum on our growth initiatives, benefits from the operational enhancement program, and category trends that continue improving as we progress through the remainder of the year. In light of our year-to-date performance, we are adjusting our projected full year effective tax rate to roughly 18% from roughly 20%. Additionally, our estimate for diluted shares outstanding in full year 2026 is now 139.6 million shares. No other guidance assumptions have been modified. As Albert said, we continue to expect results to be weighted toward the back half of the year. Operating income improved by approximately $16 million year-over-year. Let's now move to the sales outlook. As we have noted, underlying category trends improved as the second quarter progressed, and our first half net sales performance came in largely as we had expected. Accordingly, our full year outlook for both Core and all-in net sales is unchanged.
Three things underpin what we expect for how the second half performs relative to the first. First, our growth building blocks are contributing more and more — that covers innovation, gains in distribution, and demand generation — all of which are already in motion and should gather momentum as we move through the year. Second, category trends keep improving sequentially, and they gained strength during the first half of the year. Third, our base business is growing, and seasonal trends are normalizing relative to the softer seasonal performance of the prior year. Turning to guidance for 2026 adjusted earnings per share, we're being measured about the rest of the year; we stay aware of ongoing consumer weakness and macroeconomic pressures, especially in Europe. Clear, quantifiable drivers back the sequential earnings improvement in the second half, among them the revenue building blocks, the partial reduction of under-absorption tied to lower prior year sales volumes, gains from our operational enhancement program, and lower interest expense thanks to the second quarter debt paydown. Working against those sequential benefits in the second half are bigger expected advertising and promotion investments behind our demand generation and innovation launches, plus incentive compensation normalizing against the prior year. Results in the first half also carried benefits tied to the second quarter CEO transition and the recovery of tariffs. As we said earlier, planned under-absorption tied to lower prior year sales volumes should produce an unfavorable all-in earnings per share impact of about $0.60 in 2026. Of that impact, roughly $0.26 landed in the first quarter and $0.18 landed in the second quarter. To sum up, clear drivers support our second half expectations, and many of them are well underway, even as we recognize the dynamic macro environment. As Albert laid out, the Three-S plan is producing tangible improvements, and we're confident we are positioning Perrigo to deliver sustainable growth of shareholder value. Before handing the call back to Eric, I want to thank our 8,000 employees for their commitment, focus and resilience in delivering our first half results, and I look forward to continuing our progress for the remainder of the year. Eric?
Thank you, Eduardo. Operator, we're now ready for questions.
This is Ethan filling in for Chris. To kick things off, is there anything new you can share about the strategic review of the infant formula business — how it's advancing and your current thinking on when we might hear more?
Chris, Albert Manzone here, good to speak with you. Thanks for asking. As for the reviews currently underway, all of them are moving along nicely, and the moment we have anything to share, you'll hear from us. We're evaluating a range of possibilities. Like I mentioned during my opening remarks, things are progressing well, and we'll get back to you as soon as we have details.
Okay. So when you take a look at where things stand now and peer ahead toward 2027, knowing it's still early days, how do you weigh the various forces helping and hurting earnings that you're observing? And perhaps within that, which areas of the company's results give you greater conviction, and what would you say still feels less clear to you?
What I can share with you is this: a plan is in place, and it's delivering results right now. Our share is climbing, just as we told you, and as you can tell, we're pushing improvements in how we operate. We're not changing direction, and that matters greatly since I stepped into this role. This approach is the correct one. So when you consider the back half and what lies ahead, we're clearly keeping an eye on how consumers are behaving, yet we're leaning even harder into our platform-based model — whether that's on the innovation side — and I'm delighted to report, as I mentioned, that this is expanding threefold throughout our platforms. The key thing about platforms is that from one innovation and one platform, you can roll it out under a store brand and a branded label at varying price points, and if you consider that in terms of return on investment, it's a far more concentrated method and a far wiser method given who Perrigo is and what sets Perrigo apart. We're also focused on generating consumer demand and teaming up with our retail partners. Our service levels have risen. As you're aware, we're quite pleased with 95% in Europe, 91% in the U.S., though that differs by customer. But basically, this now lets us meet with them, work alongside them on building innovation and expanding not just share but the category itself in the U.S., and then producing demand generation — you'll catch some of that in the back half. So here's what I'd say about what's ahead: our aim is to have a solid plan and to outperform in execution. That's what we'll deliver, quarter after quarter.
Great. Then just one last thing from my side — how big a effect did the tariff reversal, along with any other one-time expenses, end up having on the quarter?
I'll let — yes, thanks, Chris. I'll have Eduardo take that one.
Sure. Regarding the second quarter, the tariff-related gain came to roughly $10 million, and, as I mentioned during my opening comments, the OpEx advantage tied to the CEO transition was approximately $6 million.
I'd like to revisit the private label topic — that fresh store-brand strategy in which you're allocating greater demand generation, extra marketing support, and similar resources behind those brands. Has it already been introduced at additional retailers and in other categories? From what I gather, allergy was more or less the initial one. So I'm simply wondering if you've observed a similar consumer reaction in other categories as well.
Yes. Susan, that's an excellent question. So — yes, we're applying this throughout every one of our categories; that's the response. But what I'm glad to share with you is that this is definitely where we stand and what we're doing. We can achieve this demand generation by working alongside retailers, since as you can see, we're picking up share. In the U.S., we picked up 50 basis points, and during the last 4 weeks of July we added another 60 basis points, so that's pleasing to us. Still, growing the category together with the retailers is another goal of ours. To make that happen, we have to carry out precisely the initiatives you mentioned, and we're focused on doing so throughout every category where we're present with retailers. Retailers are clearly excited, and as you're aware, once it succeeds with a couple or a few of them, it usually spreads and demand grows. So once more, our aim is to deliver and outperform on this front and with this approach, and we're eager for additional quarters resembling this one.
All right, that's great. So I suppose, regarding Infant Formula specifically, I suppose, what's your thinking on profitability as sales start to come back? Would we anticipate it moving back toward historically profitable levels? Or will it never get there again? And then I suppose, as the business does get better, I realize it's still being reviewed, but is there any consideration that maybe you'd ultimately just hold onto it?
Let me — and I'll hand this over to Eduardo, though what I'd say is that doesn't alter our strategic reviews concerning the categories we've announced. If anything, the positive here is that it provides greater optionality, obviously. So that's always a plus. A portion of it comes from the timing of shipments. So a portion of it comes from store brands. But basically, no, that doesn't alter the strategic review, and I'll have Eduardo speak more to some of the other elements of your question.
Absolutely, Susan. So beyond what Albert mentioned, I’d like to add a few points. Keep in mind, as we’ve said, that our focus will be on improving the business, working with partners, and possibly divesting certain assets, correct? When it comes to optimization, you saw that during Q2, we made some difficult, challenging calls to cut back substantially on our drying capacity in Vermont. Fortunately, we just had an FDA audit not long ago, and it turned up zero observations. That shows much of the stabilization effort we began years back proves we made the correct moves. In addition, the Secretary of HHS recently toured our facility in Wisconsin, and he came away highly impressed by the standards, calling it a state-of-the-art site for the sector. So I believe those were the right decisions on our part. They have a considerable effect on how we perform and our outcomes, but the payoff will come over the long haul. From an optimization perspective, that’s truly excellent; when it comes to quality, our initiative to get it right the first time is progressing quite well. You brought up — you noticed I said during the call that we’ve achieved a major decrease in obsolescence or scrap. The main reason is that when you get things right the first time, you gain far better absorption and lower throw rates. This has not just boosted our margin, but also enhanced how efficiently we run the business moving forward. We also enjoyed a timing-related gain tied to contract sales, which we don’t anticipate carrying over into an increase for the entire year. Still, we’re observing store brand momentum in the non-WIC market, and we’re seeing some favorable share gains for store brand, which gives us confidence there; plus, crucially, we’re noticing very encouraging early indicators from innovation — we introduced a format equivalent to one of the biggest imported rivals in the market, and those initial signals look very promising.
All right, that's helpful. If I may, I'd like to squeeze in one final item. I'm just wondering whether you have anything to say regarding the inventory situation at your retail competitors? From what I understand, a few of the branded players you compete with have mentioned some detoc — destocking taking place within OTC. I'd simply like to know whether that is having any effect on your own products.
Indeed; this is something we brought up during the opening remarks. During Q1 and Q2, we experienced a portion of that same impact. Clearly, the cause was seasonality running under typical levels. The encouraging part is that heading into the second half, it has faded; we continue to stay cautious regarding the consumer, as we previously stated, yet on our core we anticipate seasonality returning to normal, even though we won't get back to where things stood 2 years ago, though when it comes to the trends, we're cautiously optimistic.
And Susan, one more thing to tack on — we talked about how core net sales fell by roughly 3%, correct? Well, 1.8 of that came from retailers pulling down inventory, especially over in Europe.
Perhaps I should step back slightly and look at how the overall category has been performing. From what you're saying, it seems that apart from certain seasonal segments, the category is getting better. I'd really like to hear your perspective on what you believe is behind that. Clearly, your execution is getting better, and that is producing some share gains. But for quite a while, we've been taken aback to see the category remain fairly flat. And based on your comments, it sounds like things are beginning to improve and perhaps turn a corner. Keith, anything you can tell us about the reasons behind this and what's drawing shoppers back would help us map out the road ahead.
Hello, Keith, good to speak with you. Now, Ethan, on the subject of the category — as you're aware, it's been shrinking, and one factor there involves seasonal patterns, since our cough and cold period ran weak. Similarly, on the allergy front, this year's season left something to be desired. Yet toward the close of Q2 and into the early part of Q3, you begin noticing the category bouncing back. Part of this comes from the fact that seasonality is no longer a factor for us. As we've mentioned, we're anticipating a return to typical seasonal patterns moving forward, though COVID won't come back at the volumes seen two or three years ago. The second point is that we're introducing a fair amount of innovation into the market during this latter half. That covers the innovation angle. And as I mentioned, we're genuinely operating across platforms, so you should expect that platform approach—something we haven't done previously—to keep moving ahead. Looking ahead to the coming year, over half of what we bring to market will be developed on our platform. That means you'll see these offerings throughout Europe and the U.S., spanning store brand, branded products, and a range of price points. That's the first point. The second is that our strong brands—whether it's Opill, or Compeed in Europe, or Opill in the U.S.—are steadily gaining strength. To illustrate with those two: Opill in the U.S. keeps improving and expanding. Our repeat purchase rates exceed 60%, and that makes us quite pleased. This applies throughout our retail partners, and during the back half we'll be concentrating on driving consumer demand for that item, which has us quite enthusiastic. Consider Compeed in Europe — right now, in the same manner you'd reach for Kleenex when your nose needs it, across Europe people reach for Compeed for whatever their need happens to be; we've reached the top spot in France and in Italy. The U.K. had us at #1, and so did Spain. So our momentum is genuinely building. We're truly excited about the fresh product launches we've introduced. Those are performing well. Essentially, my focus remains on execution of the plan — that element means a tremendous amount to me. Strategy alone isn't enough; making it happen counts just as much. That, I believe, is the thing that will propel us onward. Naturally, we stay highly conscious of the shopper across the back half when it comes to rising prices, what people can afford, and so on. That makes us careful. Even so, our energy goes toward the areas within our grasp: partnering with retail partners to jointly create and jointly market our labels, pushing forward on new products, and building demand. Those fall inside our control. In Europe, we hold the retailer connections, and we hold the brands needed to pull that off.
Great. Perhaps only a really fast follow-up. I believe certain rivals throughout consumer health as well as personal care are encountering this pattern of channels moving. I'm interested in how you think that occurrence affects your company and how you folks believe you're set up as demand begins moving more toward — away from physical brick-and-mortar stores and more toward online shopping.
We're also noticing this, and I'm delighted to say that we're extremely much — and this is — the collection of brands we possess suits online sales above all; thus we're thrilled regarding the advancement we're achieving in U.S. online shopping, and it's expanding quite rapidly. And I'd say that in Europe, things are heading in precisely the identical way; therefore we're engaged with it; it's a priority for us, and we maintain a really robust connection. Some of those major online shopping conglomerates are — have come to see us, met with us, toured our facilities, exchanged optimal methods. And as you're aware, with regard to online shopping, meeting a person is invariably a really positive indicator, and recently many people have approached us and worked alongside us on development. So we're thrilled about the chance, and we're fully engaged with it.
Also, Keith, to hammer home the point: when it comes to e-commerce, our share gains are speeding up, and they're well ahead of what we're seeing in brick-and-mortar.
I appreciate that, Angeline. I'd also like to express my gratitude to everyone who dialed in and posed questions — they were extremely thoughtful. What I can share is that during my initial weeks, my attention has been on hearing from those with a stake in our company, and what they've told me has made me even more certain about what lies ahead for Perrigo. The customers we serve are actively involved and eager to expand their dealings with us, and that opens up a significant chance. The dedicated and talented people on our team — whom I'd like to recognize — remain devoted to our purpose of bringing affordable self-care to consumers; and there's an obvious route toward restoring investor confidence by executing consistently. That confidence will be earned by following through on what we promise, one quarter at a time. For the rest of the year, my objectives are clear: keep our market share growing by delivering on the essential pillars of growth, carry out our cost reduction initiative, push our strategic reviews forward to simplify operations further, and reach our 2026 financial targets. I'm concentrating on making sure Perrigo is set up to seize our long-term possibilities and generate lasting value for shareholders. And I have every belief that we're making the correct moves and gaining momentum throughout the company. So I'm grateful to all of you for your interest in Perrigo.
Thanks. That wraps up today’s conference call, everyone. We appreciate your participation. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Perrigo Company plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Perrigo Company plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.